| abstract |
The invention relates to novel compounds of formula (I): (See formula I) in which R a represents a hydroxyl, alkoxy or aryloxy group, arylalkyloxy, amino, alkylamino, dialkylamino, arylamino or arylalkylamino; A represents a CH group and in this case R1 represents a hydrogen atom or an alkyl group, cycloalkyl, cycloalkylalkyl, arylcarbonyl, arylcarbonylalkyl, aryloxy, aryloxyalkyl, arylthio, arylthioalkyl, arylamino, arylalkylamino, heteroaryl, heteroarylalkyl, heteroarylcarbonyl, heteroarylcarbonylalkyl, heteroaryloxy, heteroaryloxyalkyl, heteroarylthio, heteroarylthioalkyl, heteroarylamino or heteroarylalkylamino, or else A represents a nitrogen atom and in this case R1 represents a hydrogen atom or one alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylcarbonyl group, arylcarbonylalkyl, arylsulfonyl, aryloxyalkyl, arylthioalkyl, heteroaryl, heteroarylalkyl, heteroarylcarbonyl, heteroarylcarbonylalkyl, heteroaryloxyalkyl, heteroarylsulfonyl or heteroarylthioalkyl; or R1-A together represent an oxygen atom or a group (See formula II) in which R3 and R4, which are identical or different, represent an atom hydrogen or an aryl, alkyl group or a heteroaryl; R2 represents a atom hydrogen or an alkyl group; R b and R c, identical or different, represent a hydrogen or halogen, or an alkyl, alkoxy, hydroxy or trihaloalkyl; n is an integer from 2 to 6 inclusive; m and p are whole, identical or different, between 0 and 6 inclusive. The invention aims also the enantiomers and diastereoisomers of the compounds of formula (I), as well as their addition salts with a pharmaceutically acceptable acid or base. The compounds according to the invention are useful as medicaments for treatment of Atherothrombotic cardiovascular diseases, asthma, brochospasms, from the migraine and venous diseases. |